The Effect of Postsurgical Therapy on Stage III Endometrial Carcinoma

Schorge, John O.; Molpus, Kelly L.; Goodman, Annekathryn; Nikrui, Najmosama; Fuller, Arlan F.

doi:10.1006/gyno.1996.0274

Cited by 66 publications

(34 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since women with node-positive endometrioid uterine cancer have a wide range of survival from 10 to 75% (Potish et al, 1985;Larson et al, 1987;Lurain et al, 1991;Morrow et al, 1991;Rose et al, 1992;Greven et al, 1993;Schorge et al, 1996;Faught et al, 1998;Nelson et al, 1999;Mariani et al, 2002;Watari et al, 2005;Chan et al, 2006;Randall et al, 2006), several investigators have suggested substaging these patients (Nelson et al, 1999;Mariani et al, 2002;Watari et al, 2005). In this current report, our findings support the concept of stratifying node-positive cancers into substages based on nodal burden.…”

Section: Discussionsupporting

confidence: 83%

“…Prior studies have found that stage IIIC node-positive endometrial cancers comprise of only 2 -6% of all cases (Creasman et al, 1987;Lurain et al, 1991;Morrow et al, 1991;Greven et al, 1993;Schorge et al, 1996;Faught et al, 1998). Given that it is difficult for institutions to collect a large series of women with node-positive uterine cancer, this subgroup of patients has not been well studied.…”

Section: Discussionmentioning

confidence: 98%

“…Metastatic involvement of retroperitoneal lymph nodes is one of the most important prognostic factors (Morrow et al, 1991). Of the patients with node-positive disease, the estimated 5-year diseasespecific survival ranges from 10 to 75% (Potish et al, 1985;Larson et al, 1987;Lurain et al, 1991;Morrow et al, 1991;Rose et al, 1992;Greven et al, 1993;Schorge et al, 1996;Nelson et al, 1999;Mariani et al, 2002;Watari et al, 2005;Chan et al, 2006;Randall et al, 2006). The wide range of outcomes suggests that there exists considerable heterogeneity in these node-positive patients based on various clinicopathological prognostic factors.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients

et al. 2007

View full text Add to dashboard Cite

The aim of the study was to determine the impact of the absolute number and ratio of positive lymph nodes on the survival in nodepositive endometrioid uterine cancer. Data were obtained from the National Cancer Institute Registry from 1988 to 2001. Analyses were performed using Kaplan -Meier and Cox proportional hazard methods. A total of 1222 women were diagnosed with stage IIIC-IV node-positive endometrioid corpus cancer. The 5-year disease-specific survival of women with 1, 2 -5, and 45 positive nodes were 68.1, 55.1, and 46.1%, respectively (Po0.001). Increasing lymph node ratio, expressed as a percentage of positive nodes to total nodes identified (p10, 410 -p50, and 450%), was associated with a decrease in survival from 77.3 to 60.7 to 40.9%, respectively (Po0.001). The absolute number of positive nodes and the lymph node ratio remained significant after adjusting for stage (IIIC vs IV) and the extent of lymphadenectomy (p20 vs 420 nodes). On multivariate analysis, the absolute number of positive nodes and lymph node ratio were significant independent prognostic factors for survival. Increasing absolute number of positive nodes and lymph node ratio are associated with a poorer survival in women with node-positive uterine cancers. The stratification of nodepositive uterine cancer for prognostic and treatment purposes warrants further investigation.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…At different centers, patients might undergo WAI, or WP radiation, or WP plus para-aortic radiation (EFRT) [19,20]. Mundt et al [21] reviewed failure patterns among their patients and found that the optimal adjuvant radiation volume was EFRT, even in women with negative para-aortic lymph node sampling.…”

Section: Discussionmentioning

confidence: 99%

Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…These data lend support to the use of combined modality therapy in the treatment of patients with advanced stage endometrial cancer. Several studies have shown improved outcomes with combination of radiation and chemotherapy (Schorge et al 1996;Onda et al 1997;Hoskins et al 2001;Bruzzone et al 2004) and it is currently being further evaluated on a Gynecologic Oncology Group study (GOG 258: A Randomized Phase III trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma).…”

Section: Role Of Radiotherapymentioning

confidence: 99%